ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.48 and has seen 1.8 million shares traded in the recent trading session. The company, currently valued at $442.66M, closed the recent trade at $2120000.0 per share which meant it gained $2119997.52 on the day or 1796832% during that session. The ATAI stock price is 100.0% off its 52-week high price of $2.64 and 100.0% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.6 million shares traded. The 3-month trading volume is 2.12 million shares.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed 15.45%. Short interest in the company has seen 11.55 million shares shorted with days to cover at 5.41.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could drop -42399900.0% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is 100.0% off the targeted high while a plunge would see the stock lose 100.0% from the levels at last check today..
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The company’s shares have gained 67.05% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.62% over the past 5 years. Earnings growth for 2025 is a modest 44.55% while over the next 5 years, the company’s earnings are expected to increase by 32.82%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report on 2025-May-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Insiders own 8.22% of the company shares, while shares held by institutions stand at 33.40% with a share float percentage of 36.39%. Investors are also buoyed by the number of investors in a company, with ATAI Life Sciences N.V having a total of 105.0 institutions that hold shares in the company. The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7226% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.6952% of shares outstanding.
